Tandem Diabetes Care (TNDM) Cash & Current Investments (2013 - 2026)

Tandem Diabetes Care (TNDM) has 14 years of Cash & Current Investments data on file, last reported at $570.3 million in Q1 2026.

• Quarterly Cash & Current Investments rose 54.7% year-over-year to $570.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $570.3 million (up 54.7% YoY) and the FY2025 annual result came in at $292.7 million, down 33.23% from the prior year.
• Cash & Current Investments climbed to $570.3 million in Q1 2026, from $292.7 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $635.4 million in Q1 2022 to a low of $292.7 million in Q4 2025.
• A 5-year average of $481.6 million and a median of $473.3 million in 2024 frame the typical range for Cash & Current Investments.
• Annual changes were most pronounced in 2025 — Cash & Current Investments sank 33.23% — and 2026, when it surged 54.7%.
• Tracing TNDM's Cash & Current Investments over 5 years: stood at $616.9 million in 2022, then decreased by 24.15% to $467.9 million in 2023, then slipped by 6.32% to $438.3 million in 2024, then slumped by 33.23% to $292.7 million in 2025, then surged by 94.85% to $570.3 million in 2026.
• The last three Cash & Current Investments figures came in at $570.3 million (Q1 2026), $292.7 million (Q4 2025), and $319.1 million (Q3 2025), per Business Quant data.